Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells 2,290 Shares of Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 2,290 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $370.33, for a total transaction of $848,055.70. Following the completion of the transaction, the executive vice president directly owned 21,264 shares in the company, valued at $7,874,697.12. This represents a 9.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Monday, January 12th, Kevin Joseph Fitzgerald sold 1,510 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $362.87, for a total transaction of $547,933.70.
• On Monday, November 17th, Kevin Joseph Fitzgerald sold 12,128 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $452.18, for a total value of $5,484,039.04.

Alnylam Pharmaceuticals Stock Down 0.8%

Shares of ALNY stock traded down $3.10 during trading on Wednesday, hitting $366.86. 1,250,033 shares of the company were exchanged, compared to its average volume of 1,593,122. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55. The business’s 50-day simple moving average is $423.39 and its 200 day simple moving average is $421.94. The firm has a market capitalization of $48.47 billion, a price-to-earnings ratio of 1,528.58 and a beta of 0.32.

Wall Street Analyst Weigh In

ALNY has been the subject of a number of research analyst reports. Jefferies Financial Group cut their price target on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a report on Thursday, October 30th. Wall Street Zen upgraded Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 10th. Leerink Partners decreased their price objective on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a research note on Monday, December 15th. Royal Bank Of Canada raised their price target on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an “outperform” rating in a report on Friday, September 19th. Finally, Oppenheimer began coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 target price for the company. Twenty-two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $490.96.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Needham & Company reiterated a bullish outlook and forecasted strong price appreciation for ALNY, giving investors a counterpoint to bearish views and providing potential support for the stock. Needham Bullish Forecast
• Positive Sentiment: Alnylam presented at the J.P. Morgan Healthcare Conference (transcript available) — management used the forum to outline development priorities and the Alnylam 2030 growth plan, keeping the company in front of institutional investors. JPM Presentation Transcript
• Neutral Sentiment: Analysis pieces are digesting the Alnylam 2030 plan and new 2026 guidance; valuation write-ups provide scenarios but do not change fundamentals immediately. These pieces are useful for longer-term investors assessing the plan vs. current multiples. Valuation After 2030 Plan
• Neutral Sentiment: CEO interviews and conference coverage (video/interview links) elaborate on development goals and timelines; useful for due diligence but contain no immediate new financials. CEO Interview
• Neutral Sentiment: Industry roundups from JPM/BioWorld reference Alnylam within broader biopharma Q4 revenue and guidance commentary — helpful context but not company-specific catalysts. Bioworld JPM Coverage
• Neutral Sentiment: Reported short-interest data appears anomalous (shows zero shares and NaN changes), so it should not be treated as signal until corrected by exchanges. No link (data issue)
• Negative Sentiment: Insider selling: CEO Yvonne Greenstreet and multiple EVPs sold shares on Jan 12–13 (CEO sale ~9,577 shares; several EVPs sold 1,510–2,780 shares each). Collectively these disclosed sales totaled roughly $7M, which markets often view as a near-term negative signal even if sales are for personal/diversification reasons. CEO SEC Filing
• Negative Sentiment: Bank of America published a pessimistic price forecast for ALNY, which can weigh on sentiment among institutional and retail investors. BofA Pessimistic Forecast
• Negative Sentiment: News coverage highlighted a sharp intraday sell-off (article noting ~9% drop) after the company unveiled ambitious 2026 guidance and its Alnylam 2030 plan — the market appears to be re-pricing risk around execution and near-term guidance. Coverage of the Sell-off

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. OFI Invest Asset Management raised its stake in Alnylam Pharmaceuticals by 5.8% in the third quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 22 shares during the period. Howard Capital Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 2.9% in the third quarter. Howard Capital Management Inc. now owns 854 shares of the biopharmaceutical company’s stock valued at $389,000 after acquiring an additional 24 shares in the last quarter. Frank Rimerman Advisors LLC increased its holdings in shares of Alnylam Pharmaceuticals by 2.0% during the third quarter. Frank Rimerman Advisors LLC now owns 1,251 shares of the biopharmaceutical company’s stock worth $570,000 after purchasing an additional 24 shares during the period. Coastal Bridge Advisors LLC raised its holdings in Alnylam Pharmaceuticals by 2.3% in the 3rd quarter. Coastal Bridge Advisors LLC now owns 1,097 shares of the biopharmaceutical company’s stock valued at $500,000 after acquiring an additional 25 shares in the last quarter. Finally, Meridian Financial Advisors LLC grew its stake in Alnylam Pharmaceuticals by 3.5% during the third quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock worth $378,000 after buying an additional 28 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.